ERG and Familial prostate cancer: The expression of TMPRSS2—which provides the promoter for the TMPRSS2-ERG fusion, presents in about 50% of organ-confined prostate cancers, the commonest genetic abnormality in prostate cancer, [10,53] is strongly regulated by RME.